Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | LATS1 | O95835 | 5/20 | 0.37 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662287 | 0.86 | HASPIN (0.42) | HASPINLMNACLK1ABCB1CA12 | |
| SCHEMBL3816236 | 0.77 | KDM4E (0.59) | ACHELMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL250853 | 0.77 | ACHE (0.42) | ACHELATS1LATS2KDM4CLMNA | |
| SCHEMBL26157957 | 0.76 | DCPS (0.55) | ACHELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1623074 | 0.72 | HRH4 (0.42) | ACHELMNACYP1A2ABCB1KDM4E | |
| SCHEMBL31377414 | 0.71 | HRH4 (0.43) | ACHELMNACYP1A2ABCB1KDM4E | |
| SCHEMBL21875480 | 0.70 | LATS1 (0.61) | LATS1LATS2 | |
| SCHEMBL30443506 | 0.69 | HASPIN (0.49) | HASPINCLK1CA12CA1CA2 | |
| SCHEMBL29936384 | 0.69 | HASPIN (0.33) | HASPINLMNAABCB1KDM4EALDH1A1 | |
| SCHEMBL31662056 | 0.69 | KDM4E (0.39) | HASPINLMNACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | claimed |
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | claimed |
| EP-1697361-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005066171-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | MKI67, MYC, CCNK | HASPIN 640/4885ACHE 4587/4885LATS1 301/4885 |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | HASPIN 3099/4885ACHE 3754/4885LATS1 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.